1672 Overzicht aandelen Ascletis Pharma Inc. is een biotechnologiebedrijf dat zich bezighoudt met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland. Meer informatie
Risicoanalyse Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
Ascletis Pharma Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Ascletis Pharma Historische aandelenkoersen Huidige aandelenkoers HK$4.12 52 Week Hoogtepunt HK$4.50 52 Week Laag HK$0.76 Bèta 0.58 1 maand verandering 29.56% 3 maanden verandering 172.85% 1 Jaar Verandering 139.53% 3 jaar verandering -9.85% 5 jaar verandering 1.23% Verandering sinds IPO -70.57%
Recent nieuws en updates
Ascletis Announces Positive Results from U.S. Single Ascending Dose Study of Small Molecule Oral Gp-1R Agonist ASC30 Jan 21
Founder recently bought HK$916k worth of stock Jan 15
New minor risk - Share price stability Dec 28
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans? Oct 07 Meer updates bekijken
Ascletis Announces Positive Results from U.S. Single Ascending Dose Study of Small Molecule Oral Gp-1R Agonist ASC30 Jan 21
Founder recently bought HK$916k worth of stock Jan 15
New minor risk - Share price stability Dec 28
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans? Oct 07
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
New minor risk - Revenue size Sep 06
New minor risk - Share price stability Aug 29
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 Apr 03
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 26
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Mar 11
Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 Feb 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne Jan 24
New major risk - Revenue and earnings growth Jan 09
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis Jan 02
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate Dec 19
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne Dec 05
First half 2023 earnings: EPS exceeds analyst expectations Sep 30
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 29
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Sep 27
Consensus revenue estimates decrease by 19%, EPS upgraded Aug 29
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely Aug 23
First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022) Aug 23
New major risk - Revenue and earnings growth Aug 23
Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023 Jul 24
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis Jul 22
New minor risk - Profitability Jul 19
Consensus revenue estimates decrease by 22%, EPS upgraded Jul 19
Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023 Jun 06
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection May 09
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 21
Forecast breakeven date moved forward to 2023 Mar 21
Consensus revenue estimates decrease by 12% Feb 25
Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B Feb 17
Consensus revenue estimates increase by 27% Feb 14
Forecast breakeven date moved forward to 2023 Feb 14
Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Feb 01
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa Jan 27
Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 Jan 17
Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc Jan 03
Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19 Dec 13
Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA Dec 08
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne Dec 02
Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA Nov 30
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA Nov 24
Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA Nov 18
Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA Nov 16
Insufficient new directors Nov 16
Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022 Nov 07
What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today Nov 03
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Nov 03
Consensus revenue estimates fall by 19% Nov 01
Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication Oct 27
Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth Oct 13
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19 Oct 11
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash Oct 06
Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 28
Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22 Sep 16
Consensus revenue estimates fall by 13% Aug 29
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates Aug 24
First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021) Aug 23
Ascletis Pharma Inc. Announces Change of Company Secretary Aug 23
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA Aug 22
Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis Aug 17
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors Aug 08
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA Aug 05
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients Aug 04
Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022 Jul 28
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19 Jul 07
Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection Jul 05
Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection Jun 29
Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022 Jun 28
Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 Jun 16
Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer Jun 13
Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022 May 25
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation May 19 Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application
Forecast to breakeven in 2023 Apr 27
Insufficient new directors Apr 27
Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 Apr 20
Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration Apr 07
Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication Mar 31
Consensus revenue estimates increase by 54% Mar 28
Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022 Mar 28
Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts Mar 27
Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022 Mar 04
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Mar 01
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Feb 28
Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients Feb 15
Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant Feb 08
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely Feb 08
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Feb 07
Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA Jan 27 Rendement voor aandeelhouders 1672 HK Biotechs HK Markt 7D 3.5% 5.6% 1.4% 1Y 139.5% 17.5% 26.5%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 1672 overtrof de Hong Kong Biotechs industrie, die het afgelopen jaar een rendement 17.5 % opleverde.
Rendement versus markt: 1672 overtrof de Hong Kong markt, die het afgelopen jaar een rendement opleverde van 26.5 %.
Prijsvolatiliteit Is 1672's price volatile compared to industry and market? 1672 volatility 1672 Average Weekly Movement 14.1% Biotechs Industry Average Movement 7.8% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.8% 10% least volatile stocks in HK Market 3.0%
Stabiele aandelenkoers: De aandelenkoers van 1672 is de afgelopen 3 maanden volatiel geweest in vergelijking met de Hong Kong markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van 1672 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Hong Kong.
Over het bedrijf Ascletis Pharma Inc., een biotechnologiebedrijf, houdt zich bezig met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland. Het bedrijf biedt een Ritonavir-tablet en ASCLEVIR en GANOVO voor de behandeling van het hepatitis C-virus. Het ontwikkelt ook ASC22 voor de behandeling van CHB en HIV functionele genezing; ASC10 voor respiratoir syncytievirus; ASC10 en ASC11 voor de behandeling van COVID-19; ASC40, ASC41, ASC42, ASC43F FDC voor niet-alcoholische steatohepatitis; en ASC42 voor de behandeling van primaire biliaire cholangitis.
Meer tonen Ascletis Pharma Inc. Samenvatting Hoe verhouden de winst en inkomsten van Ascletis Pharma zich tot de beurswaarde? 1672 fundamentele statistieken Marktkapitalisatie HK$3.97b Inkomsten(TTM ) -HK$275.43m Inkomsten(TTM ) HK$10.75m
369.1x P/S-verhouding
-14.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 1672 resultatenrekening (TTM ) Inkomsten CN¥10.09m Kosten van inkomsten CN¥22.72m Brutowinst -CN¥12.63m Overige uitgaven CN¥245.84m Inkomsten -CN¥258.47m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.27 Brutomarge -125.17% Nettowinstmarge -2,561.68% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde 1672 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/12 19:11 Aandelenkoers aan het einde van de dag 2025/02/12 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten Ascletis Pharma Inc. wordt gevolgd door 6 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Ling Zhang China Merchants Securities (HK) Co., Ltd Mingrui Wang Everbright Securities Co. Ltd. Siao Ye Everbright Securities Co. Ltd.
Toon 3 meer analisten 
